Subtype
Lung Non-Squamous Non-Small Cell Carcinoma
CI-CAN-00005826Explore in graph →
93 active trials5 approved drugs127 evidence items
- NCIt
- C135017
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005826Explore in graph →
Clinical trials
408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER |
| 1 |
| Dec 13, 2022 |
| clinicaltrials |
| NCT05346952 | A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | unknown | Phase 3 | 390 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04416035 | A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC(NSCLC) | unknown | Phase 3 | 608 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT03992885 | Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. | unknown | Phase 3 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT02011997 | Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion(cVATS) | unknown | Phase 3 | 500 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Dec 16, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2023source: clinicaltrials